GSK3B and breast cancer: Previously, we observed that introducing KD-GSK-3β into MCF-7 breast cancer cells increased their resistance to the chemotherapeutic drug doxorubicin and the hormonal based drug tamoxifen in comparison to MCF-7 cells that inherited WT-GSK-3β [37].